Latest California Healthline Stories
Trump Vows (Again) To Lower Drug Prices But Skeptics Doubt Much Will Change
President Donald Trump’s much-awaited speech about slashing drug costs was long on rhetoric but short on specifics that will reduce prices.
Why Did Novartis Pay Trump’s Lawyer $1.2 Million? Look At Its Drug Prices
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
Podcast: KHN’s ‘What The Health?’ The Politics Of Rising Premiums And Menu Labeling
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Margot Sanger-Katz of The New York Times and Anna Edney of Bloomberg News discuss the latest on the politics of rising premiums, GOP efforts to take back money from the Children’s Health Insurance Program, and the controversy over new rules requiring calorie information on menus. Plus for extra credit, the panelists recommend their favorite health stories of the week.
Listen: Psychotropic Drug Use Up Sharply As Jails House More People With Mental Illness
The use of psychiatric drugs among inmates in California’s county jails has soared 25 percent in five years. California Healthline reporter Anna Gorman discussed this phenomenon in a recent radio interview.
‘Pharma Bro’ Shkreli Is In Prison, But Daraprim’s Price Is Still High
The saga of Martin Shkreli and Turing Pharmaceuticals focused a lot of attention on prescription drug prices, but no reversal of the exponential price increases for the lifesaving drug Daraprim resulted. The story offers an object lesson into the interworkings of the pharmaceutical market.
Use Of Psychiatric Drugs Soars In California Jails
A combination of factors has led to an “astronomical” increase in mentally ill inmates, followed by increased efforts to identify those who need prescriptions. Some say the meds are underprescribed; others, that they are given inappropriately, without the benefit of comprehensive treatment.
How A Drug Company Under Pressure For High Prices Ratchets Up Political Activity
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
Dissecting The Rhetoric Vs. Reality Of Trump’s Tough Talk On Drug Prices
President Donald Trump’s upcoming speech on drug prices comes after months of public comments and debate about tackling the issue.
Readers Weigh In On Vitamin Use And The Big Pharma-Patient Advocacy Connection
California Healthline and Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Podcast: KHN’s ‘What The Health?’ Nothing In Health Care Ever Goes Away
In this episode of KHN’s “What the Health?” Sarah Jane Tribble of Kaiser Health News, Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Paige Winfield Cunningham of The Washington Post examine how even after Republicans failed to repeal and replace the Affordable Care Act, the health care debate continues to roil politics. They discuss how Republicans in Congress have shifted their ACA messaging and how the Democrats are looking to Medicare expansion. They also discuss state efforts to expand Medicaid and drug pricing. And they spend a moment talking about Congress’ push to do something about the opioid crisis.